Market research
8BV1.F Primo Nutraceuticals Inc
F EUR Healthcare
Latest close
Latest stored close unavailable
Test a moving-average rule with historical data.
Market facts
- Market cap
- 550K
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.14
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- Not available
- Market cap
- 550K
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.14
About
About Primo Nutraceuticals Inc
Primo Nutraceuticals Inc. owns and develops commercial real estate properties for the cannabis cultivation sector in Canada. It offers built out turnkey facilities equipped with infrastructure to cannabis growers and processors. It owns hemp project in Oregon state and the greenhouse campus in Washington state. The company was formerly known as Bougainville Ventures Inc. and changed its name to Primo Nutraceuticals Inc. in October 2019. Primo Nutraceuticals Inc. was incorporated in 2014 and is based in Vancouver, Canada.
Research context
Primo Nutraceuticals Inc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 8BV1.F discussion.
5 years, 7 months ago
Primo Nutraceuticals Inc is currently in a long term uptrend where the price is trading 36.7% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, Primo Nutraceuticals Inc gets an overall score of 2/5.